Azoximer bromide: Difference between revisions
link corrected |
typo |
||
| Line 1: | Line 1: | ||
{{Expand Russian|topic= |
{{Expand Russian|topic=sci|Азоксимера бромид|date=July 2015}} |
||
{{Infobox drug |
{{Infobox drug |
||
| drug_name = |
| drug_name = |
||
Revision as of 01:14, 18 March 2017
 | You can help expand this article with text translated from the corresponding article in Russian. (July 2015) Click [show] for important translation instructions.
|
 | |
| Clinical data | |
|---|---|
| Other names | Polyoxidonium, Synpol |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | up to 89% |
| Elimination half-life | 25.4 hours (intravenous routes) |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | [[C8H15BrN2O2]x[C6H12N2O]y]n |
| Molar mass | 60000–100000 g/mol |
Azoximer bromide is a macromolecular compound with high-molecular weight and high immunomodulating activity. It is used in Russia and CIS in treatment and prophylaxis of diseases connected with damage of immune system. It is a N-oxidized polyethylene–piperazine derivative.
Azoximer bromide is registered in US Patent-5503830 from 1996,[1][2][3] in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00.[4]
Medical uses
In adults with secondary immunodeficient states as
- relapsing chronic bacterial infections
- relapsing chronic viral infections
- acute bacterial infections
- acute viral infections
- allergic diseases (pollinosis, bronchial asthma, atopic dermatitis)
- severe septic states
- postoperative complications - purulent infections
- when primary treatment develops cellular immunity decrease (cytostatic treatment, X-rays)
References
- ^ http://www.google.com/patents/about?id=s9cfAAAAEBAJ&dq=US+5503830
- ^ http://www.wikipatents.com/US-Patent-5503830/compounds-having-immunostimulating-activity-and-methods-of-use-thereof[permanent dead link]
- ^ http://www.freepatentsonline.com/EP0789586.html
- ^ State Scientific Centre of Russian federation, Immunological Institute of Russian Federation Health Resort, CLINICAL ASPECTS OF USE OF IMMUNOMODULATOR POLYOXIDONIUM, Methodical handbook for doctors issued by State Scientific Centre of Russian Federation – Immunological Institute of Russian Federation Health Resort Moscow – 2003
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |